Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/ACM.0000000000000724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease.
CNS Drugs
January 2025
Innovative Medicines and Global Clinical Development, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Background: Huntington disease (HD) is a progressive neurodegenerative disease that causes psychiatric and neurological symptoms, including involuntary and irregular muscle movements (chorea). Chorea can disrupt activities of daily living, pose safety issues, and may lead to social withdrawal. The vesicular monoamine transporter 2 inhibitors tetrabenazine, deutetrabenazine, and valbenazine are approved treatments that can reduce chorea.
View Article and Find Full Text PDFUse of AI in Family Medicine Publications: A Joint Editorial from Journal Editors.
J Am Board Fam Med
January 2025
Affiliations: Editor in Chief, Family Medicine; Department of Family Medicine and Community Health, School of Medicine and Public Health, University of Wisconsin, Health Sciences Learning Center750 Highland Avenue Madison, WI (SS); Deputy Editor, Journal of the American Board of Family Medicine; Department of Family and Community Medicine, Medical College of Georgia,Augusta University, Augusta, GA (DAS); Editor in Chief, American Family Physician and FP Essentials; Department of Family Medicine, Georgetown University School of Medicine, Washington DC (SMS); Editor in Chief, Annals of Family Medicine; Alpert Medical School, Brown University, Richmond St, Providence, RI (CRR); Editor in Chief, Evidence-Based Practice; University of Washington/Valley Medical Center FMR, Renton, WA (JN); Scientific Editor, Canadian Family Physician; Department of Family and Community Medicine, University of Toronto, Ontario (NP); Editor in Chief, Journal of the American Board of Family Medicine; Veterans Health Administration (MAB); Deputy Editor, Family Medicine; Family and Preventive Medicine, Spencer Fox Eccles School of Medicine, University of Utah Health, Salt Lake City, UT (JR); Editor in Chief, PRiMER; Departments of Public Health & Preventive Medicine and Family Medicine, SUNY Upstate Medical University, Weiskotten Hall, NY (CPM); Editor in Chief, Family Medicine and Community Health; Department of Family Medicine, University of Virginia, VA (LL); Medical Editor, FPM; Pioneer Physicians Network (JDD).
Definition and diagnostic criteria of clinical obesity.
Lancet Diabetes Endocrinol
January 2025
Division of Diabetes & Nutritional Sciences, School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London, UK; Catholic University of the Sacred Heart, Rome, Italy; University Polyclinic Foundation Agostino Gemelli IRCCS, Rome, Italy.
Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.
Lancet Diabetes Endocrinol
January 2025
Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, VIC, Australia; Department of Endocrinology, Monash Health, Clayton, VIC, Australia.
Background: Primary aldosteronism can be treated medically but there is no standardised method to evaluate treatment outcomes. We aimed to develop criteria for assessing the outcomes of targeted medical treatment of primary aldosteronism, analyse outcomes across an international cohort, and identify factors associated with a complete treatment response.
Methods: An international panel of 31 primary aldosteronism experts used the Delphi method to reach consensus on the definition of complete, partial, or absent biochemical and clinical outcomes of medical treatment of primary aldosteronism.
Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial.
PLoS One
January 2025
Interventional Psychiatry Program, St. Michael's Hospital, Toronto, Ontario, Canada.
Background: Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonstrated efficacy in treating chronic PTSD, a substantial proportion of patients still continue to meet PTSD criteria after treatment, highlighting the need for novel therapeutic approaches.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!